Details of the Drug

General Information of Drug (ID: DMJFZDL)

Drug Name
Naphazoline
Synonyms
Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole
Indication
Disease Entry ICD 11 Status REF
Hyperaemia 9A61-9B7Y Approved [1]
Itching 1F28-1G07 Approved [1]
Therapeutic Class
Anticancer Agents
ATC Code
R01AA08: Naphazoline
R01AA: Sympathomimetics, plain
R01A: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01: NASAL PREPARATIONS
R: RESPIRATORY SYSTEM
R01AB02: Naphazoline
R01AB: Sympathomimetics, combinations excl. corticosteroids
R01A: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01: NASAL PREPARATIONS
R: RESPIRATORY SYSTEM
S01GA01: Naphazoline
S01GA: Sympathomimetics used as decongestants
S01G: DECONGESTANTS AND ANTIALLERGICS
S01: OPHTHALMOLOGICALS
S: SENSORY ORGANS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 210.27
Logarithm of the Partition Coefficient (xlogp) 2.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-2 h []
Half-life
The concentration or amount of drug in body reduced by one-half in 4 - 8 hours [2]
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C14H14N2
IUPAC Name
2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole
Canonical SMILES
C1CN=C(N1)CC2=CC=CC3=CC=CC=C32
InChI
InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)
InChIKey
CNIIGCLFLJGOGP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4436
ChEBI ID
CHEMBL761
CAS Number
835-31-4
UNII
H231GF11BV
DrugBank ID
DB06711
TTD ID
D0O6IZ
ACDINA ID
D01273
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hyperaemia
ICD Disease Classification 9A61-9B7Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Naphazoline (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Moderate Decreased metabolism of Naphazoline caused by Methylene blue mediated inhibition of non-CYP450 enzyme. Acquired methaemoglobinaemia [3A93] [4]
Levomilnacipran DMV26S8 Moderate Increased risk of rapid heart rate by the combination of Naphazoline and Levomilnacipran. Chronic pain [MG30] [5]
Ozanimod DMT6AM2 Moderate Decreased metabolism of Naphazoline caused by Ozanimod mediated inhibition of non-CYP450 enzyme. Multiple sclerosis [8A40] [4]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Benzalkonium chloride E00536 21988052 Antimicrobial preservative; Penetration agent; Solubilizing agent; Surfactant
Thimerosal E00529 16684434 Antimicrobial preservative
Edetate disodium E00186 8759 Complexing agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Water E00035 962 Solvent
Boric acid E00152 7628 Antimicrobial preservative; Buffering agent
Camphor E00060 2537 Antimicrobial preservative; Flavoring agent; Plasticizing agent
Sodium borate E00511 11954323 Alkalizing agent; Antimicrobial preservative; Buffering agent; Emulsifying agent
Sodium sulhydrate E00549 23665763 Antimicrobial preservative
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Naphazoline 0.05% solution 0.05% Solution Topical
Naphazoline 0.012% solution 0.01% Solution Ophthalmic
Naphazoline 0.01% solution 0.01% Solution Ophthalmic
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Toxnet: Naphazoline Hydrochloride
3 Decongestants in treatment of nasal obstruction. Otolaryngol Pol. 1999;53(3):347-52.
4 Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
5 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.